Aquinox Pharmaceuticals Inc. (AQXP) Issues Quarterly Earnings Results
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) posted its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.12.
Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 12.95 on Friday. Aquinox Pharmaceuticals has a 52 week low of $6.01 and a 52 week high of $15.76. The stock has a 50 day moving average of $12.08 and a 200 day moving average of $9.46. The company’s market cap is $222.90 million.
Several research firms have weighed in on AQXP. Needham & Company LLC restated a “buy” rating on shares of Aquinox Pharmaceuticals in a research report on Thursday. Zacks Investment Research upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 4th. Canaccord Genuity restated a “buy” rating and issued a $22.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Wednesday, August 17th. Leerink Swann began coverage on shares of Aquinox Pharmaceuticals in a research report on Tuesday, October 4th. They issued an “outperform” rating and a $24.00 price objective for the company. Finally, Jefferies Group raised their price objective on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research report on Friday, August 5th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Aquinox Pharmaceuticals currently has an average rating of “Buy” and an average target price of $20.00.
In other news, major shareholder Bros. Advisors Lp Baker bought 2,783,605 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The shares were bought at an average cost of $12.25 per share, for a total transaction of $34,099,161.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.00% of the stock is owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. KCG Holdings Inc. purchased a new position in shares of Aquinox Pharmaceuticals during the third quarter worth about $438,000. Morgan Stanley boosted its position in shares of Aquinox Pharmaceuticals by 41.5% in the third quarter. Morgan Stanley now owns 12,715 shares of the company’s stock worth $169,000 after buying an additional 3,732 shares in the last quarter. Northern Trust Corp boosted its position in shares of Aquinox Pharmaceuticals by 26.2% in the third quarter. Northern Trust Corp now owns 64,033 shares of the company’s stock worth $856,000 after buying an additional 13,301 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Aquinox Pharmaceuticals by 10.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 220,071 shares of the company’s stock worth $2,940,000 after buying an additional 20,414 shares in the last quarter. Finally, BlackRock Investment Management LLC boosted its position in shares of Aquinox Pharmaceuticals by 23.7% in the third quarter. BlackRock Investment Management LLC now owns 25,358 shares of the company’s stock worth $339,000 after buying an additional 4,858 shares in the last quarter. Institutional investors own 65.89% of the company’s stock.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Stock Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.